Livmarli (Maralixibat Chloride) Patent Expiration, LOE Window & CMS Spending

Livmarli (Maralixibat Chloride) by Mirum Pharmaceuticals: FDA Orange Book LOE 2040-02-12, 0 AB generics, $92.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMirum Pharmaceuticals
FDA Application & PathwayN214662 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-02-12
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$92.1M
2024 Medicare Part D Spend$7.9M
2024 Medicaid Spend$84.2M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 21.7% 2-yr change)